Status:
COMPLETED
Clinical Efficacy of Trastuzumab in Combination With Capecitabine and Oxaliplatin for the Treatment of HER2-positive Advanced Gastric Cancer.
Lead Sponsor:
Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
Conditions:
Advanced Gastric Carcinoma
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
Trastuzumab plus chemotherapy prolonged the median overall survival in patients with human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer (AGC). Among chemotherapy regimens...
Eligibility Criteria
Inclusion
- HER2-positive AGC defined as either HER2 immunohistochemistry (IHC) 3+ or IHC 2+ and fluorescence in situ hybridization (FISH)+ with no history of previous treatment.
Exclusion
- \-
Key Trial Info
Start Date :
March 1 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 30 2023
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT05997524
Start Date
March 1 2021
End Date
June 30 2023
Last Update
August 18 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Bangabandhu Sheikh Mujib Medical University
Dhaka, Bangladesh, 1000